Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980669193> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W1980669193 endingPage "298" @default.
- W1980669193 startingPage "294" @default.
- W1980669193 abstract "The two leading therapeutic areas for biological products, in terms of current sales and pipeline focus, are oncology and AIID (arthritis, immune and inflammatory disorders). Datamonitor's biotechnology strategic market analysis team recently analysed the AIID market, since this sector is currently powering biotechnology market growth, owing to high demand for biologicals to treat rheumatoid arthritis and psoriasis (Belsey, M. and Churchill, C. (2006) 'Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010', J. Comm. Biotechnol., Vol. 12, No. 2, pp. 237–241). In the current paper, we have analysed the oncology market, since biologicals designed to treat cancer indications have underpinned the development of the biotechnology market since its inception in the 1980s. Biological products treat a wide variety of cancers, of which the most prevalent are the 'big four' tumour types – breast cancer, lung cancer, prostate cancer and colorectal cancer. In terms of technology focus, both monoclonal antibody therapeutics and recombinant proteins are set to drive cancer biological market growth. Key growth drivers include mainly Genentech and Roche products, such as Avastin (bevacizumab), Rituxan (rituximab) and Herceptin (trastuzumab), as well as Amgen products, including the second-generation recombinant proteins Neulasta (pegfilgrastim) and Aranesp (darbepoetin alfa). Across the major pharmaceutical markets, oncology biologicals generated US$10.7bn in 2004 (based on company-reported data), which Datamonitor forecasts to rise to US$29.0bn by 2010." @default.
- W1980669193 created "2016-06-24" @default.
- W1980669193 creator A5011981641 @default.
- W1980669193 creator A5070069129 @default.
- W1980669193 date "2006-07-01" @default.
- W1980669193 modified "2023-10-15" @default.
- W1980669193 title "Cancer remains the dominant disease target for biotech through to 2010" @default.
- W1980669193 cites W1976513080 @default.
- W1980669193 cites W2054312635 @default.
- W1980669193 cites W2158134441 @default.
- W1980669193 doi "https://doi.org/10.1057/palgrave.jcb.3040179" @default.
- W1980669193 hasPublicationYear "2006" @default.
- W1980669193 type Work @default.
- W1980669193 sameAs 1980669193 @default.
- W1980669193 citedByCount "4" @default.
- W1980669193 countsByYear W19806691932013 @default.
- W1980669193 crossrefType "journal-article" @default.
- W1980669193 hasAuthorship W1980669193A5011981641 @default.
- W1980669193 hasAuthorship W1980669193A5070069129 @default.
- W1980669193 hasConcept C121608353 @default.
- W1980669193 hasConcept C126322002 @default.
- W1980669193 hasConcept C143998085 @default.
- W1980669193 hasConcept C150903083 @default.
- W1980669193 hasConcept C2776694085 @default.
- W1980669193 hasConcept C2777802072 @default.
- W1980669193 hasConcept C2779338263 @default.
- W1980669193 hasConcept C2779786085 @default.
- W1980669193 hasConcept C2780192828 @default.
- W1980669193 hasConcept C2780653079 @default.
- W1980669193 hasConcept C530470458 @default.
- W1980669193 hasConcept C59491497 @default.
- W1980669193 hasConcept C71924100 @default.
- W1980669193 hasConcept C86803240 @default.
- W1980669193 hasConceptScore W1980669193C121608353 @default.
- W1980669193 hasConceptScore W1980669193C126322002 @default.
- W1980669193 hasConceptScore W1980669193C143998085 @default.
- W1980669193 hasConceptScore W1980669193C150903083 @default.
- W1980669193 hasConceptScore W1980669193C2776694085 @default.
- W1980669193 hasConceptScore W1980669193C2777802072 @default.
- W1980669193 hasConceptScore W1980669193C2779338263 @default.
- W1980669193 hasConceptScore W1980669193C2779786085 @default.
- W1980669193 hasConceptScore W1980669193C2780192828 @default.
- W1980669193 hasConceptScore W1980669193C2780653079 @default.
- W1980669193 hasConceptScore W1980669193C530470458 @default.
- W1980669193 hasConceptScore W1980669193C59491497 @default.
- W1980669193 hasConceptScore W1980669193C71924100 @default.
- W1980669193 hasConceptScore W1980669193C86803240 @default.
- W1980669193 hasIssue "4" @default.
- W1980669193 hasLocation W19806691931 @default.
- W1980669193 hasOpenAccess W1980669193 @default.
- W1980669193 hasPrimaryLocation W19806691931 @default.
- W1980669193 hasRelatedWork W1993762334 @default.
- W1980669193 hasRelatedWork W2106302600 @default.
- W1980669193 hasRelatedWork W2412746179 @default.
- W1980669193 hasRelatedWork W2597812774 @default.
- W1980669193 hasRelatedWork W2905813014 @default.
- W1980669193 hasRelatedWork W2914532353 @default.
- W1980669193 hasRelatedWork W2980572115 @default.
- W1980669193 hasRelatedWork W4229777120 @default.
- W1980669193 hasRelatedWork W4231642484 @default.
- W1980669193 hasRelatedWork W4385064586 @default.
- W1980669193 hasVolume "12" @default.
- W1980669193 isParatext "false" @default.
- W1980669193 isRetracted "false" @default.
- W1980669193 magId "1980669193" @default.
- W1980669193 workType "article" @default.